10.1111/j.1600-079X.2007.00499.x 244 Wolden-HansonT.MittonD
For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in Instructions. Instructions: All submissions received must include the Docket No
Med Oncol (2022) 39(2):26
It can change when the amount of enzyme, substrate, SAM, test time, or detection method changes
Nanomedicine and gene therapy represent another frontier of IDD treatment, with potential advancements in mitochondria-targeted nanoparticle design, such as TAT-PEG-MitoQ, to enhance drug delivery efficiency while reducing systemic toxicity
JS: Writing original draft, Writing review & editing